European CHMP recommends approval of tirbanibulin mesylate (Klisyri) for treatment of actinic keratosis

The full indication for this non-ATP competitive Src kinase inhibitor is for the treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. Klisyri will be available as 10 mg/g ointment.

Source:

European Medicines Agency